The Oncology Institute, Inc. beat EPS estimates 50% of the time across 6 reported quarters (3 beats, 3 misses), averaging -15.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.07 | not reported | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | not reported | $-0.02 | not reported | not reported | |
| Q4 FY25 | $-0.08 | $-0.06 | +25.0% | Beat | |
| Q1 FY25 | $-0.08 | $-0.14 | -75.0% | Miss | |
| Q1 FY24 | $-0.11 | $-0.21 | -90.9% | Miss | |
| Q1 FY23 | $-0.17 | $-0.10 | +41.2% | Beat | |
| Q4 FY22 | $-0.18 | $-0.16 | +11.1% | Beat | |
| Q3 FY22 | $-0.16 | $-0.17 | -6.3% | Miss | |
| Q2 FY22 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY22 | not reported | $-0.29 | not reported | not reported | |
| Q4 FY21 | not reported | $0.26 | not reported | not reported | |
| Q3 FY21 | not reported | $-0.04 | not reported | not reported |
Back to TOI overview · TOI holders · TOI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.